| Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies W Li, H Zhang, YG Assaraf, K Zhao, X Xu, J Xie, DH Yang, ZS Chen Drug Resistance Updates 27, 14-29, 2016 | 699 | 2016 |
| Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2 JH Hooijberg, HJ Broxterman, M Kool, YG Assaraf, GJ Peters, ... Cancer Research 59 (11), 2532-2535, 1999 | 605 | 1999 |
| Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance A Shapira, YD Livney, HJ Broxterman, YG Assaraf Drug resistance updates 14 (3), 150-163, 2011 | 601 | 2011 |
| Modulating ROS to overcome multidrug resistance in cancer Q Cui, JQ Wang, YG Assaraf, L Ren, P Gupta, L Wei, CR Ashby Jr, ... Drug Resistance Updates 41, 1-25, 2018 | 579 | 2018 |
| Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein R Oerlemans, NE Franke, YG Assaraf, J Cloos, I van Zantwijk, CR Berkers, ... Blood, The Journal of the American Society of Hematology 112 (6), 2489-2499, 2008 | 550 | 2008 |
| Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance N Gonen, YG Assaraf Drug Resistance Updates 15 (4), 183-210, 2012 | 548 | 2012 |
| The multi-factorial nature of clinical multidrug resistance in cancer YG Assaraf, A Brozovic, AC Gonçalves, D Jurkovicova, A Linē, ... Drug resistance updates 46, 100645, 2019 | 470 | 2019 |
| Lysosomes as mediators of drug resistance in cancer B Zhitomirsky, YG Assaraf Drug Resistance Updates 24, 23-33, 2016 | 455 | 2016 |
| Molecular basis of antifolate resistance YG Assaraf Cancer and Metastasis Reviews 26, 153-181, 2007 | 446 | 2007 |
| The folate receptor as a rational therapeutic target for personalized cancer treatment YG Assaraf, CP Leamon, JA Reddy Drug Resistance Updates 17 (4-6), 89-95, 2014 | 409 | 2014 |
| Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance KJ Gotink, HJ Broxterman, M Labots, RR De Haas, H Dekker, ... Clinical Cancer Research 17 (23), 7337-7346, 2011 | 375 | 2011 |
| Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance M Bar-Zeev, YD Livney, YG Assaraf Drug Resistance Updates 31, 15-30, 2017 | 339 | 2017 |
| The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis YG Assaraf Drug Resistance Updates 9 (4-5), 227-246, 2006 | 291 | 2006 |
| Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance S Narayanan, CY Cai, YG Assaraf, HQ Guo, Q Cui, L Wei, JJ Huang, ... Drug Resistance Updates 48, 100663, 2020 | 266 | 2020 |
| Cyclic nucleotide-binding domains in proteins having diverse functions JB Shabb, JD Corbin The Journal of biological chemistry 267 (9), 5723-5726, 1992 | 256 | 1992 |
| Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach S Taylor, EP Spugnini, YG Assaraf, T Azzarito, C Rauch, S Fais Drug Resistance Updates 23, 69-78, 2015 | 244 | 2015 |
| Taxanes in cancer treatment: Activity, chemoresistance and its overcoming L Mosca, A Ilari, F Fazi, YG Assaraf, G Colotti Drug Resistance Updates 54, 100742, 2021 | 243 | 2021 |
| The role of passive transbilayer drug movement in multidrug resistance and its modulation GD Eytan, R Regev, G Oren, YG Assaraf Journal of biological chemistry 271 (22), 12897-12902, 1996 | 243 | 1996 |
| Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance B Zhitomirsky, YG Assaraf Oncotarget 6 (2), 1143, 2014 | 237 | 2014 |
| Potentiation of anticancer‐drug cytotoxicity by multidrug‐resistance chemosensitizers involves alterationsin membrane fluidity leading to increased membrane permeability S Drori, GD Eytan, YG Assaraf European journal of biochemistry 228 (3), 1020-1029, 1995 | 237 | 1995 |
